Marking Addiction Awareness Week
TheraCryf plc is supporting Addiction Awareness Week by highlighting its lead Ox-1 orexin-1 blocker program, which targets binge eating disorder and other substance use disorders. The program is progressing on budget and ahead of schedule, with manufacturing of 2kg human grade material initiated and scale-up to 10kg proceeding as planned, aiming for clinic readiness by the end of 2026. The company also holds robust patent protection for Ox-1 in major territories including Europe and the USA, with a recent grant in Korea. This development is significant given that addiction costs the UK economy over £21 billion annually and is a cause of substantial mortality.
Select text to share a quote on X · sign in to keep highlights & notes in your TCF notes
Alderley Park, 26 November 2025 - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain disorders, is supporting Addiction Awareness Week.
23-30 November is the UK's national Addiction Awareness Week 2025, aiming to raise awareness of the challenges and stigma around addiction.
Addictions, particularly Substance Use Disorders, are a chronic, relapsing group of disorders with a high unmet medical need. The number of people affected is astonishing, with up to 2.2% of the global population estimated to have a Substance Use Disorder[1]. Current treatments often see high relapse rates, and there are limited long-term pharmacological options.
Last year in the UK, addiction was the cause of more deaths than road traffic collisions, and it costs the economy more than £21bn per year. Alcohol addiction alone costs the NHS more than £3.5bn per year.
TheraCryf is honoured to be contributing to the potential treatment of addiction with its lead Ox-1 orexin -1 blocker programme, targeting binge eating disorder and other substance use disorders.
As noted earlier this month, the programme is progressing on budget and ahead of schedule, with the 0.5kg scale-up completed ahead of schedule, manufacturing of 2kg human grade material initiated and the scale-up to 10kg manufacturing proceeding to plan. This is with our aim of achieving clinic readiness by the end of 2026.
TheraCryf has also has robust patent protection for Ox-1, with the recent patent grant in Korea, complementing long lasting patent protection in all major territories including Europe and USA.
Dr Huw Jones, CEO of TheraCryf, said:
"In marking Addiction Awareness Week, we are conscious of the very real unmet medical need in addiction. Addictive disorders affecting hundreds of millions of people and their families across the world, with the global cost burden running into many tens of billions. We are focused on helping to reduce both the human and financial costs of these conditions and getting our promising Ox-1 programme into the clinic as soon as possible."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.